All In Biotech

Drug Trial Radar · NCT05128591

A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091

An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover, Phase 1 Study Under Fed State to Evaluate the Safety and Pharmacokinetics of AD-109 in Healthy Male Volunteers

Last checked: Nov 19, 2026Latest source record: Mar 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Nov 9, 2021

Primary completion

Dec 31, 2021

Study completion Dec 31, 2021

Sponsor

Lead sponsor
Addpharma Inc.Industry
Sponsor type
Industry
First posted
Nov 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-109 in healthy male subjects.

Conditions

  • Embolism and Thrombosis

Interventions

  • Rivaroxaban 18mg Oral TabletDrug

    AD-109 (Rivaroxaban 18mg) Oral Tablet

  • Rivaroxaban 20 MG Oral TabletDrug

    AD-1091 (Rivaroxaban 20mg) Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak Plasma Concentration (Cmax)Time frame: pre-dose to 34 hours
  2. Area Under the Curve in time plot (AUCt)Time frame: pre-dose to 34 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • H+ Yangji Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.